Subrata Das

Subrata Das has extensive experience in the pharmaceutical industry, specializing in the development and manufacturing of inhalation products. Subrata is currently employed at PYC Therapeutics as the Senior Director of Chemistry, Manufacturing, and Controls, and Head of Drug Product Development. Prior to this, Das worked at Axar Pharmaceuticals, Inc. as the Director of Product Development from 2014 to 2021. In this role, they led the formulation development of various dosage forms such as Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers, Nasal, Ophthalmic, and Sublingual formulations. Das also contributed to CMC activities, including manufacturing process development, scale-up, and technology transfer. Subrata supervised inhalation CMC, product characterization, and conducted in vitro bioequivalence studies.

From 2008 to 2014, Das held several roles at Actavis plc, including Senior Principal Pharmaceutical Technology Specialist and Principal Pharmacist. During this time, they managed third-party contract manufacturing and analytical testing of inhalation products and served as a technical lead for their commercialization. Subrata also played a key role in the CMC aspects of product development, managing CROs and CMOs for testing and manufacturing, conducting deformulation and feasibility studies, and leading prototype formulation development.

Before joining Actavis, Das worked at Catalent as a Lead Scientist from 2005 to 2008. In this role, they focused on CMC development and evaluation of nasal, sublingual spray, nebulizers, pMDI, and DPI products. Subrata conducted feasibility studies, prototype formulation development, and supervised lab-scale manufacturing process development.

Das began their career as a Principal Scientist at Morton Grove Pharmaceuticals in 2004, where they focused on the development of generic Metered Dose Nasal Spray formulations containing peptides, proteins, and corticosteroids. Subrata conducted deformulation, reverse engineering, preformulation, and formulation development.

Prior to working in the private sector, Das was a Senior Scientist at the CBR Institute for Biomedical Research, Harvard Medical School, from 2001 to 2004. Here, they led a team for IND application submission to the FDA and developed protein drug products for pulmonary delivery. Subrata also established a cGMP analytical inhalation laboratory and in-house manufacturing capability.

Das began their career in 1998 as an Associate Research Scientist at Yale University School of Medicine. Their work focused on the development of vaccines against Lyme disease, including characterization, formulation, and studying the immunological and molecular biological aspects of Lyme disease pathogenesis.

Overall, Subrata Das has a wealth of experience in the pharmaceutical industry, particularly in the development and manufacturing of inhalation products, with a strong background in formulation development, CMC activities, and commercialization.

Subrata Das completed their Ph.D. in Physiology and Biochemistry from Louisiana State University, where they studied from 1987 to 1992. Prior to that, they obtained an MS degree in Zoology from the University of Calcutta. The specific years of their education at the University of Calcutta are not provided.